ArticleJournal of neurology2026
Prevalence and characteristics of patients with seronegative myasthenia gravis.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myasthenia gravis is an autoimmune disorder characterized by antibodies targeting the neuromuscular junction, causing fatigue of skeletal muscle. Natural history and epidemiological studies report that around 10% of patients diagnosed with myasthenia gravis do not have detectable levels of antibodies, categorized as seronegative. Theories of the pathophysiology in these patients are predominantly centered around undetectable antibody titers and antibodies against yet undefined antigens in the neuromuscular junction. This study aims to investigate the regional prevalence and characteristics of patients with seronegative myasthenia gravis. This study is a retrospective chart review of 350 patients with myasthenia gravis treated at the Copenhagen Neuromuscular Center. Of these, 15 (4.3%) were seronegative and 335 (95.7%) were seropositive. No differences were found when comparing the two groups on demographics, symptom profile, comorbidities, treatment, and diagnostic delay. The frequency of seronegative myasthenia gravis patients was lower in this cohort than previously reported. Seronegative myasthenia gravis patients were essentially indistinguishable from seropositive patients on all parameters evaluated. These findings correspond well with the emerging evidence of a similar pathophysiology in the two groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.